圆桌论坛上，陆文超分享了公司在创新征程上的探索与实践。"十四五"期间，公司坚持"研发创新+外延 发展"双轮驱动，以临床价值为导向，致力于开发和引进满足临床需求的优质药品。陆文超以公司成功 引进突破性创新药"速必一"为例，向与会人员阐释了该产品的重要价值。公司锚定研发创新改革，利用 合成生物技术对传统业务进行革命性升级，打造合成生物"第二增长曲线"。此外，公司以战略引领为核 心，以产品、商业模式、实现方式与组织能力四维并举，依托卓越的战略执行力确保各项目标扎实落 地，推动公司在高质量发展的道路上行稳致远。在最新发布的2025年中国化药企业TOP100排名中，华 润双鹤在民企林立的格局中成功突围，新晋至第13位。 中证报中证网讯（王珞）10月29日，以"向新而行 以实致远 智启未来"为主题的2025上市公司高质量发 展论坛暨第二十七届上市公司金牛奖颁奖典礼在江苏南通举行，备受瞩目的上市公司金牛奖榜单正式揭 晓。华润双鹤董事长陆文超荣膺"金牛企业家创新奖"，并受邀出席主题圆桌论坛，与知名企业家共 话"新质生产力下的价值创造之路"。 上市公司金牛奖是中国证券报主办的金牛系列评选活动之一，创立于1999年，活动采取严谨 ...

Core Viewpoint - The company reported a slight decline in revenue and net profit for Q1 2025, primarily due to high base effects and weakened demand in the large infusion segment, but maintains a positive outlook for steady profit growth in 2025 driven by product upgrades and new market explorations [1][2]. Group 1: Financial Performance - Q1 2025 revenue reached 3.079 billion yuan, a year-over-year decrease of 2.10%, with net profit attributable to shareholders at 507 million yuan, down 1.26% year-over-year [1]. - The large infusion segment saw a revenue decline of 16% year-over-year, totaling 770 million yuan, attributed to high base effects and seasonal demand fluctuations [1]. - Non-infusion segment revenue for Q1 2025 was 2.28 billion yuan, reflecting a year-over-year increase of 3.35%, driven by growth in gynecology and oncology specialties [2]. Group 2: Segment Analysis - The large infusion segment is expected to stabilize in sales volume, with ongoing upgrades in packaging and production efficiency to maintain profit levels despite revenue declines [1]. - The non-infusion segment's growth is supported by steady performance in chronic disease treatments and strong sales in specialty areas, particularly gynecology and oncology [2]. - The raw materials segment experienced an 8.7% year-over-year revenue decline, but is anticipated to recover due to new product introductions and improved sales volumes [2]. Group 3: Growth Potential - The company has established eight core technology platforms and is advancing over 20 key projects, indicating a robust pipeline for future growth [2]. - Expansion into e-commerce and OTC channels is expected to contribute to a targeted revenue growth of 10% in 2025 [2]. - New product launches, including innovative drugs for diabetes and antiviral treatments, are projected to drive revenue growth, supported by a strong sales team [2]. Group 4: Profit Forecast and Valuation - The company forecasts EPS of 1.69, 1.83, and 1.96 yuan for 2025, 2026, and 2027 respectively, with a target price of 27.04 yuan based on a 16x PE ratio for 2025 [3].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 27.04 RMB [7][8]. Core Views - The company reported Q1 2025 revenue of 3.079 billion RMB (down 2.10% year-on-year) and a net profit of 507 million RMB (down 1.26% year-on-year), primarily due to a high base in the large infusion segment and weakening demand [1]. - Despite a slight decline in the large infusion segment, the company is expected to see steady net profit growth in 2025, driven by packaging upgrades and an increase in the proportion of nutritional and therapeutic infusions [1][4]. - The non-infusion segment showed robust growth, with Q1 2025 revenue of 2.28 billion RMB (up 3.35% year-on-year), supported by steady performance in chronic disease products and strong growth in specialty areas like gynecology and oncology [3]. Summary by Sections Infusion Segment - Q1 2025 revenue for the infusion segment was 770 million RMB (down 16% year-on-year), affected by high base effects and seasonal demand fluctuations [2]. - The company anticipates a slight decline in revenue for the large infusion segment but expects to maintain profit levels through cost reductions via packaging upgrades and automation [2]. Non-Infusion Segment - The non-infusion segment's revenue growth is driven by chronic disease products and specialty areas, with a 15% year-on-year increase in the specialty segment due to the launch of new oncology products [3]. - The raw material drug segment experienced an 8.7% year-on-year decline, but the company expects recovery in 2025 due to new product launches and improved sales [3]. Potential Growth Points - The company has established eight core technology platforms and has over 20 core projects in development, indicating a strong pipeline for future growth [4]. - The expansion into e-commerce and OTC channels is expected to contribute to a 10% revenue growth target for 2025 [4]. Profit Forecast and Valuation - The company’s EPS is projected to be 1.69 RMB for 2025, with a PE ratio of 16 times, aligning with the industry average [5][6]. - The revenue forecast for 2025 is 11.605 billion RMB, reflecting a growth rate of 3.51% [6].